cell therapy

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients. The site describes arming cells against cancer and announces the sale of TECELRA, lete-cel, afami-cel and uza-cel cell therapies to US WorldMeds.

cancer immunotherapy development

ImmunityBio is a biotechnology company founded in 2014 that develops immunotherapies and cell therapies designed to activate both innate and adaptive immune responses to treat cancer and infectious diseases. Its lead product, ANKTIVA (nogapendekin alfa inbakicept), is FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer. The company also develops a natural killer cell platform and potential cancer vaccines.

clinical trialsimmunotherapy developmentnatural killer cell platformresearch and manufacturing

Asclepii is a regenerative medicine and wound care company that develops Poseidon™, an FDA-cleared nanosilver hydrogel wound dressing designed to support moisture balance and topical wound management. The company serves clinics and providers, distributors and resellers, and patients and caregivers, and offers a clinical evaluation program for healthcare organizations.

nanotechnologyregenerative medicinewound care

CDI Labs provides proteomic products and services for autoantibody profiling, biomarker discovery, target identification, and antibody development. Its platforms include the HuProt™ Human Proteome Microarray (21,000+ full-length human proteins) and PhIP-Seq services such as HuScan®, MouseScan™, VirScan®, and VirScan® Exposome. The company also offers specialized CRO services including antibody development, protein production, cell therapy, and immunogenicity testing.

antibody developmentbiomarker discoveryCRISPR-Cas9 immunogenicity testingdiagnostic developmentimmunogenicity testingmolecular glue discoverypan-proteome epitope mappingPhIP-Seqpost-translational modification specificity profilingprotein microarrayprotein productionproteome-wide autoantibody profilingtarget identification

ImmunoShield Therapeutics is a biotechnology company developing an enabling platform for allogeneic cell therapy designed to protect therapeutic cells and support long-term function after implantation, with a focus on treating Type 1 Diabetes. The company builds a technology layer that complements and strengthens therapeutic programs, aiming to improve protection, persistence, and practicality of implanted insulin-secreting cells without broad immune suppression.

biomaterialscell transplantationimmune engineering

Programming B Cells to Deliver Novel Therapies for Patients How We’re Doing It Immusoft is the world leader in engineering B cells as biofactories for therapeutic protein delivery, a novel approach that we have pioneered. Our platform, called Immune System Programming (ISP™) entails collecting a type of the patient’s immune cells, called B cells. In response to immune stimulation, B cells can turn into biofactories (known as plasma cells), each of which manufactures and secretes thousands of antibodies per second. We harness this biofactory capability of the plasma cell by programming B cells to produce personalized protein therapeutics. Once we have programmed the B cells, we then expand and differentiate into plasma cells that will then produce large amounts of our therapeutic protein. In the clinic, we then infuse the programmed cells back into the patient, where they take up.

B cell engineeringclinical developmentplasma cell differentiationpreclinical research